Novartis subsidiary Alcon has secured European CE Mark for its AcrySof IQ PanOptix trifocal intraocular lens (IOL) for patients undergoing cataract surgery.
The approval targets patients, who opted to use a single lens to address their near, intermediate and distance vision requirements.
Alcon Surgical Franchise Research and Development head Franck Leveiller said: “The AcrySof IQ PanOptix trifocal IOL is a significant innovation which further augments Alcon’s presbyopia correcting portfolio, leveraging Alcon’s market-leading AcrySof IQ IOL platform.
“It is designed to provide exceptional functional vision from near to intermediate, in addition to providing excellent distance vision.”
The AcrySof IQ PanOptix trifocal IOL is indicated for adult patients with and without presbyopia undergoing cataract surgery who seek near, intermediate and distance vision with increased spectacle independence.
More than three million cataract surgeries are performed each year in Europe.
The majority of patients undergoing cataract surgery experience compromised near vision, without presbyopia-correcting IOLs, and require additional vision correction after surgery such as reading glasses or multifocal contact lenses.
Arnott Eye Associates director Richard Packard said: “Today’s patients undergoing cataract surgery are more likely to seek vision correction options to address various lifestyle tasks such as reading books, using electronic tablets, working on computers and performing outdoor activities without the need for glasses or contact lenses.
“The AcrySof IQ PanOptix trifocal IOL is an important option that should provide these patients with a full range of vision and thus significantly reduced dependence on glasses.”
Caused by clouding of the natural lens of the eye that affects vision, a cataract is claimed to be the leading cause of preventable blindness in adults over the age of 55.
Image: A cataract in the human eye. Photo: courtesy of Rakesh Ahuja, MD.